Method Development and Assessment of the Effects of Tobacco Products on Oral Cavity Cells
NCT01484769 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2017-04-10
Summary
Collection of tissues for analysis from patients undergoing elective neck dissection.
The hypothesis of the study is that specific genetic alterations occur in head and neck cancers that have spread to regional and/or distant sites, and these alterations can be identified from biopsy specimens to allow more accurate staging of tumor and better treatment planning.
Conditions
Sponsors & Collaborators
-
University of Louisville
lead OTHER
Eligibility
- Min Age
- 7 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-07-31
- Primary Completion
- 2011-06-30
- Completion
- 2012-06-30
Countries
- United States
Study Locations
More Related Trials
-
Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
NCT02572778 ·Status: RECRUITING
-
Discovering Factors in Head and Neck Cancer Patients' Clinical Study Experiences
NCT05801770 ·Status: NOT_YET_RECRUITING
-
Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer
NCT01053546 ·Status: TERMINATED ·Phase: NA
-
Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial
NCT01619618 ·Status: COMPLETED
-
Patient Evaluation for Head and Neck Surgery Branch Studies
NCT00011492 ·Status: TERMINATED
-
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
NCT00049140 ·Status: COMPLETED ·Phase: PHASE2
-
Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers
NCT04086849 ·Status: COMPLETED
-
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging
NCT04222543 ·Status: UNKNOWN ·Phase: PHASE2
-
Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy
NCT01194635 ·Status: COMPLETED
-
Survival Analysis of Oral Cancer Patients
NCT04967638 ·Status: COMPLETED
-
Studying Survivorship Care Plans in Head and Neck Cancer
NCT03106090 ·Status: TERMINATED ·Phase: NA
-
Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
NCT00357617 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
H&N Cancer; Survivorship and Late Effects
NCT04758026 ·Status: COMPLETED
-
Quantitative Optical Sensor Findings in Head & Neck Squamous Cell Carcinoma
NCT02943044 ·Status: UNKNOWN
-
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NCT04333537 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
NCT06794372 ·Status: RECRUITING ·Phase: PHASE2
-
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
NCT05268614 ·Status: RECRUITING ·Phase: PHASE2
-
Prognostic Value of CTC in HNSCC Patients
NCT01884129 ·Status: TERMINATED
-
Training Swallowing Initiation During Expiration
NCT05278039 ·Status: COMPLETED ·Phase: NA
-
Comprehensive Assessment of Head and Neck Cancer Survivors
NCT01222481 ·Status: COMPLETED
-
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
NCT03010150 ·Status: RECRUITING
-
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT00939627 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
NCT01921426 ·Status: COMPLETED ·Phase: PHASE1
-
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT01412229 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397
NCT01466244 ·Status: COMPLETED